Abstract:We congratulate Serra-Aracil and colleagues1Serra-Aracil X. Pericay C. Badia-Closa J. et al.Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).Ann Oncol. 2023; 34: 78-90Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar on the completion of the clinical trial that compared chemoradiotherapy (CRT) and transanal endoscopic microsurgery (TEM) versus total mesorectal excision (TME) among patients with T2-T3ab,N0,M0 rectal cancer. However, the findings raise several crucial concerns and should be interpreted carefully. First, one of the most essential advantages of combining preoperative CRT with TEM surgery is preserving the rectum as well as obtaining similar oncological results. The inclusion criteria of the participant in this study required rectal adenocarcinomas located up to 10 cm from the anal verge. Actually, the median distance from the anal verge of the included population was 6.6 cm. In the present clinical guideline, height from the anal margin plays a crucial role in the decision making of the range of surgical resection. For patients with rectal cancer with a distance from the anal verge >5 cm, TEM surgery does not necessarily require anal resection. Therefore we recommend that the authors conduct a subgroup analysis by distance from the anal verge, the results of which are essential for interpreting the clinical practice meaning of this study. Second, some patients in this study may have been undertreated. In this study, 21% (17/81) of patients had positive lymph nodes after surgery in the TME group, which represents the counterfactual of the treatment group in a setting of a randomized control trial.2Hernán M.A. Robins J.M. Causal Inference. CRC, Boca Raton, FL2010Google Scholar This would imply that there was also ∼21% probability of positive lymph nodes in the CRT-TEM group. We wonder if the authors considered that patients in the CRT-TEM group might require further postoperative adjuvant chemotherapy. Third, adverse event assessment is an essential aspect of treatment evaluation among patients with rectal cancer. However, the reporting of adverse effects in this study is not yet comprehensive, such as bone marrow suppression, not listed in Table 4, which is a common adverse effect of CRT. We suggest the authors disclose more detailed information on adverse events to improve the comprehensive evaluation between the two groups. Finally, this study design of time interval between CRT and TEM surgery might be problematic. A longer interval between the end of CRT and surgery is associated with a better pathological complete response (pCR) rate via a series of prospective and retrospective studies; that is, surgery at week 12 after CRT had better oncological results than surgery at week 8 after CRT.3Lefevre J.H. Mineur L. Kotti S. et al.Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6).J Clin Oncol. 2016; 34: 3773-3780Crossref PubMed Scopus (346) Google Scholar We recommend that future studies should take time interval into consideration in the of design. None declared.

Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Prognostic value of lateral lymph node metastasis in pretreatment MRI for rectal cancer in patients undergoing neoadjuvant chemoradiation followed by surgical resection without lateral lymph node dissection: A systemic review and meta-analysis

The efficacy of adjuvant chemotherapy after total mesorectal excision with selective lateral pelvic node dissection for lower rectal cancer.

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Long-term efficacy of preoperative chemoradiotherapy combined with total mesorectal excision for locally advanced rectal cancer: an analysis of 241 patients

Preoperative lateral lymph node features and impact on local recurrence after neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: results from a multicentre international cohort study

Oncologic Outcomes of ypT1-3N0&nbsp;mid-Low Rectal Cancer Compared&nbsp;with pT1-3N0 Disease After Radical Resection

Feasibility, Indications and Prognostic Significance of Selective Dissection after Preoperative Chemoradiotherapy in Middle/Low Rectal Cancer with Clinical Suspected Lateral Pelvic Lymph Node Involvement: Results of the Multicenter Lateral Node Study in China

Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy

Association of Lateral Pelvic Lymph Nodes with Disease Recurrence and Organ Preservation in Patients with Distal Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy

Identification of lateral pelvic nodes without metastasis in patients with rectal cancer treated with preoperative chemoradiotherapy or chemotherapy based on magnetic resonance imaging

Role of Adjuvant Chemotherapy After Curative Resection in Stage II and III Rectal Cancer

Oncologic Outcomes of ypT1-3N0 mid-Low Rectal Cancer Compared with pT1-3N0 Disease After Radical Resection

[Occult Lymph Node Metastasis in the Middle and Lower Third Rectal Cancer after Neoadjuvant Radiotherapy].

Lymphovascular Invasion in Rectal Cancer Following Neoadjuvant Radiotherapy: a Retrospective Cohort Study.

MRI‐based parameters and clinical risk factors to predict lymph node metastasis in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy

Effects of neoadjuvant chemotherapy with or without intensity‐modulated radiotherapy for patients with rectal cancer

The Results of Preoperative Chemoradiation Followed by Surgery on Rectal Cancer Patients Diagnosed MRF+ or T4b

In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer

The Role of Chemoradiotherapy in Organ Preservation for Rectal Cancer